Merck's eye disease drug meets main goal in trial
Merck's eye disease drug meets main goal in trial Sept 24 (Reuters) - Merck MRK.N said on Thursday its drug met the main goal in a mid- to late-stage trial testing it in adult patients with a type of disease that affects blood vessels at the back of the eye.
(Reporting by Christy Santhosh in Bengaluru; Editing by Sahal Muhammed)
Recent news on Merck & Co
See all newsBrief: European Commission Approves Keytruda Plus Padcev As Perioperative Treatment For Adults With Resectable Muscle-Invasive Bladder Cancer
US STOCKS-Dow leads Wall Street higher, investors focus on healthcare stocks
Moderna recoups part of losses as BofA raises PO ahead of key cancer vaccine readout
Live Markets: Dot-com deja vu? Why Goldman Sachs is calling time on the momentum trade
Factbox: Pharma sector doubles down on AI to slash costs, timelines